New study aims to personalize metastatic breast cancer treatment with molecular subtype info

NCT ID NCT03769415

Recruiting now Knowledge-focused Sponsor: UNC Lineberger Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether giving doctors the molecular subtype of a patient's metastatic breast cancer helps them pick more effective treatments. It involves 500 adults with metastatic breast cancer who are starting or have had one prior treatment. The main goal is to see how often this new information changes the doctor's treatment plan.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

UNC Lineberger Comprehensive Cancer Center
RECRUITING

Chapel Hill, North Carolina, 27599, United States
UNC Rex Healthcare
RECRUITING

Raleigh, North Carolina, 27607, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.